Insights

Non-invasive cancer Speclipse offers the world’s first laser-induced plasma spectroscopy based cancer diagnostic solution with AI, enabling real-time, non-invasive skin cancer diagnosis. This presents a compelling value proposition for dermatology clinics, cancer centers, and telemedicine platforms seeking to reduce unnecessary biopsies and improve patient throughput.

Early-stage funding With recent venture funding of 7.7M and a total funding of 10M, there is evidence of investor confidence and a runway for product development and regional expansion. Sales teams can leverage this momentum to secure pilots with flagship clinics and accelerate adoption cycles.

Awards & visibility Recognition as a Top 10 Non Invasive Device Company enhances credibility in MedTech pipelines and procurement discussions. This can be used in outreach to healthcare networks, hospitals, and distributors looking for trusted, innovative diagnostic partners.

Cloud and web-ready Tech stack includes Google Cloud CDN, HTTP/3 and modern web tooling, signaling scalable, secure deployment and potential integration with hospital information systems and digital health platforms. This creates opportunities for partnerships with IT teams seeking compliant, high-performance devices and data pipelines.

Small team, nimble With a lean team and global recognition, Speclipse can be a strategic partner for pilots, white-label opportunities, and co-development ventures with larger device manufacturers or diagnostic networks seeking to innovate without large onboarding overhead.

Similar companies to Speclipse, Inc.

Speclipse, Inc. Tech Stack

Speclipse, Inc. uses 8 technology products and services including Wix, WordPress, Wix eCommerce, and more. Explore Speclipse, Inc.'s tech stack below.

Speclipse, Inc.'s Email Address Formats

Speclipse, Inc. uses at least 2 email formats:
Speclipse, Inc. Email FormatsExamplePercentage
First@speclipse.comJohn@speclipse.com
50%
First.Last@speclipse.comJohn.Doe@speclipse.com
50%

Frequently Asked Questions

What is Speclipse, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Speclipse, Inc.'s official website is speclipse.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Speclipse, Inc. generate?

Minus sign iconPlus sign icon
As of August 2026, Speclipse, Inc.'s annual revenue is estimated to be $1M - $10M.

What is Speclipse, Inc.'s NAICS code?

Minus sign iconPlus sign icon
Speclipse, Inc.'s NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Speclipse, Inc. have currently?

Minus sign iconPlus sign icon
As of August 2026, Speclipse, Inc. has approximately 9 employees across 2 continents, including North America and Oceania. Key team members include Cto, Co-Founder: W. M., Chief Marketing Officer: B. 본. G. 구. and Global Medical Director: S. S. Explore Speclipse, Inc.'s employee directory with LeadIQ.

What industry does Speclipse, Inc. belong to?

Minus sign iconPlus sign icon
Speclipse, Inc. operates in the Medical Device industry.

What technology does Speclipse, Inc. use?

Minus sign iconPlus sign icon
Speclipse, Inc.'s tech stack includes Wix, WordPress, Wix eCommerce, Google Workspace, Google Cloud, Sentry, YouTube and Google Analytics.

What is Speclipse, Inc.'s email format?

Minus sign iconPlus sign icon
Speclipse, Inc.'s email format typically follows the pattern of First@speclipse.com. Find more Speclipse, Inc. email formats with LeadIQ.

How much funding has Speclipse, Inc. raised to date?

Minus sign iconPlus sign icon
As of August 2026, Speclipse, Inc. has raised $10M in funding. The last funding round occurred on Sep 19, 2021 for $7.7M.

When was Speclipse, Inc. founded?

Minus sign iconPlus sign icon
Speclipse, Inc. was founded in 2015.
Speclipse, Inc. logo

Speclipse, Inc.

Medical DeviceCalifornia, United States2-10 Employees

Speclipse, Inc. is a medical device developer based in Sunnyvale, California, focused on creating non-invasive diagnostic solutions for skin cancer. Its flagship technology supports real-time in-vivo diagnosis without compromising diagnostic accuracy, aiming to reduce unnecessary biopsies and assist physicians in making more informed patient assessments. The company operates within the medical equipment manufacturing sector and targets clinicians and healthcare providers seeking advanced diagnostic tools for challenging skin-cancer cases.

With a small team, Speclipse positions itself at the intersection of laser spectroscopy and artificial intelligence to advance cancer diagnostics and expand potential applications of its core technology. The company has gained recognition in industry circles as an innovative non-invasive device developer, highlighted by its inclusion in external rankings and its ongoing development efforts in the field. The organization is based in the San Francisco Bay Area region and appears focused on advancing its diagnostic capabilities while supporting physicians in delivering patient-centered care.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2015
Employees
2-10

Section iconFunding & Financials

  • $10M

    Speclipse, Inc. has raised a total of $10M of funding over 3 rounds. Their latest funding round was raised on Sep 19, 2021 in the amount of $7.7M as a Venture Round.

  • $1M - $10M

    Speclipse, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.